Wall Street Zen upgraded shares of Polyrizon (NASDAQ:PLRZ – Free Report) from a strong sell rating to a hold rating in a report issued on Saturday morning.
Polyrizon Stock Up 0.9%
NASDAQ PLRZ opened at $1.13 on Friday. The firm’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $41.22. Polyrizon has a 12-month low of $0.55 and a 12-month high of $1,200.00.
Institutional Investors Weigh In On Polyrizon
A hedge fund recently bought a new stake in Polyrizon stock. Citadel Advisors LLC acquired a new stake in shares of Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 38,337 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.91% of Polyrizon at the end of the most recent reporting period.
About Polyrizon
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Read More
- Five stocks we like better than Polyrizon
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How The Weak Dollar Is Fueling These Global Stock Surges
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Recession-Ready Stocks That Thrive When the Economy Sputters
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Automation-Focused Stocks Flying Under the Radar
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
